William Blair Has Pessimistic View of Danaher Q3 Earnings

Danaher Corporation (NYSE:DHR - Free Report) - Analysts at William Blair reduced their Q3 2025 earnings per share estimates for shares of Danaher in a report released on Wednesday, July 23rd. William Blair analyst M. Larew now anticipates that the conglomerate will earn $1.72 per share for the quarter, down from their previous estimate of $1.88. The consensus estimate for Danaher's current full-year earnings is $7.63 per share. William Blair also issued estimates for Danaher's Q4 2025 earnings at $2.32 EPS, FY2025 earnings at $7.72 EPS, Q1 2026 earnings at $2.13 EPS, Q3 2026 earnings at $1.91 EPS, Q4 2026 earnings at $2.55 EPS and FY2026 earnings at $8.61 EPS.

Other research analysts have also recently issued research reports about the company. Deutsche Bank Aktiengesellschaft decreased their target price on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Evercore ISI decreased their target price on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. JPMorgan Chase & Co. decreased their target price on Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a research note on Tuesday, April 22nd. Barclays reiterated an "overweight" rating and issued a $225.00 price target (up previously from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Finally, Wolfe Research reduced their price objective on Danaher from $275.00 to $220.00 and set an "outperform" rating for the company in a research note on Monday, April 7th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $247.61.

Danaher Price Performance

DHR stock traded up $2.79 during trading hours on Thursday, hitting $205.60. 5,355,676 shares of the stock traded hands, compared to its average volume of 3,965,185. The stock has a 50-day simple moving average of $196.38 and a 200 day simple moving average of $203.68. Danaher has a one year low of $171.00 and a one year high of $281.70. The company has a market cap of $147.22 billion, a P/E ratio of 43.74, a P/E/G ratio of 2.86 and a beta of 0.77. The company has a current ratio of 1.62, a quick ratio of 1.05 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The firm had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same period last year, the company earned $1.72 earnings per share. The firm's revenue for the quarter was up 3.4% on a year-over-year basis.

Institutional Trading of Danaher

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FAS Wealth Partners Inc. grew its holdings in Danaher by 20.6% in the 4th quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock valued at $2,203,000 after buying an additional 1,639 shares during the last quarter. Asahi Life Asset Management CO. LTD. acquired a new stake in Danaher in the 1st quarter valued at approximately $539,000. Horizon Financial Services LLC grew its holdings in shares of Danaher by 20,400.0% during the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock worth $1,681,000 after purchasing an additional 8,160 shares in the last quarter. Vision Capital Management Inc. acquired a new stake in shares of Danaher during the 1st quarter worth approximately $461,000. Finally, Eos Management L.P. grew its holdings in shares of Danaher by 55.8% during the 1st quarter. Eos Management L.P. now owns 40,567 shares of the conglomerate's stock worth $8,316,000 after purchasing an additional 14,537 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Insider Buying and Selling

In related news, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the transaction, the executive vice president directly owned 15,179 shares of the company's stock, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the transaction, the chairman directly owned 3,105,808 shares in the company, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by company insiders.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 25th. Investors of record on Friday, June 27th were paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.62%. Danaher's payout ratio is 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.